COPD is progressive and the structural damage is irreversible. Cell therapy has been tested in it, the results are modest and mostly negative on function, and the safety data are reassuring. Here is all of it.
## ⛔ NOTHING ON THIS PAGE IS A REASON TO CHANGE YOUR OXYGEN
Long-term oxygen therapy is prescribed because it prolongs life in chronic hypoxaemia. It is not a
comfort measure and it is not a mobility inconvenience to be escaped. **Reducing it because you feel
better — without measured improvement in your blood oxygen — can kill you.**
⚠️ No trial of stem cell therapy in COPD has shown any reduction in oxygen requirement. Not one.
Any claim that this treatment reduces or removes the need for oxygen is unsupported, wherever you
meet it — a clinic's brochure, a testimonial, or a page like this one.
**The same applies to your inhalers, your steroids, your pulmonary rehabilitation attendance and your
transplant assessment.** Oxygen flow rates are changed by the physician who prescribed them, on the basis
of measured oxygenation. Never on the basis of how a treatment made you feel.
What COPD Is, and What Standard Care Achieves
COPD affects hundreds of millions of people worldwide and is among the leading causes of death [1]. It is a progressive inflammatory lung disease with persistent, not fully reversible airflow limitation [5][7], and its definition and nomenclature remain under active revision by the field [6]. Two pathologies run together: chronic bronchitis — airway inflammation, mucus, fibrotic narrowing — and emphysema, the destruction of alveolar walls that enlarges airspaces and reduces the surface available for gas exchange.
⚠️ The alveolar destruction is permanent. Lung parenchyma does not regenerate in adults. Any therapy for COPD is working on inflammation, on the airways, on what remains — not on rebuilding lost tissue.
What actually works, at full strength
⭐ Smoking cessation. The only intervention demonstrated to alter the rate of lung-function decline in COPD. ⚠️ Nothing else on this page comes close, and any treatment decision that displaces it is a bad trade. Roughly a quarter of COPD occurs in never-smokers [10], but where smoking is the driver, stopping is the treatment.
⭐ Pulmonary rehabilitation. Strong evidence for exercise capacity, breathlessness and quality of life. Requires ongoing participation, which is why it is under-used — but it is among the best-evidenced interventions in respiratory medicine.
Inhaled therapy. Bronchodilators and, in selected patients, inhaled corticosteroids, per GOLD [2][7].
Long-term oxygen therapy. ⚠️ In chronic hypoxaemia this prolongs life. It is prescribed on measured oxygenation and titrated by a physician; duration of daily use matters to outcome [8][9].
Vaccination, nutrition, and — in selected patients — surgical volume reduction or transplantation.
What the Cell Therapy Trials Found
The landmark trial, reported in full
*Weiss et al. 2013, Chest — randomised, double-blinded, placebo-controlled. 62 patients at six sites with moderate-to-severe COPD received four monthly intravenous infusions of 100 million allogeneic MSCs or vehicle, and were followed for two years* [12].
On efficacy — the result was negative:
"There were no significant differences in PFTs or quality-of-life indicators."
"There were no significant differences in the overall number of adverse events, frequency of COPD exacerbations, or worsening of disease."
On inflammation — one positive signal:
"An early, significant decrease in levels of circulating C-reactive protein (CRP) was observed in patients treated with MSCs who had elevated CRP levels at study entry."
⚠️ CRP is a blood marker of inflammation, not a measure of breathing. It moved; lung function and quality of life did not.
⭐ On safety — genuinely reassuring, and the most important result here:
"All study patients completed the full infusion protocol, and 74% completed the 2-year follow-up. There were no infusional toxicities and no deaths or serious adverse events deemed related to MSC administration."
Two years of follow-up in patients with moderate-to-severe COPD, with no treatment-attributable serious harm, is a substantial finding. It is the strongest thing this page can honestly tell you.
The pooled evidence
Calzetta et al. 2022 — systematic review and meta-analysis, 371 COPD patients across 11 studies [13]:
The authors' own conclusion: "the current evidence comes from small clinical trials. Large and well-designed randomized controlled trials are needed to really quantify the beneficial impact."
⚠️ A 52-metre gain on a walking test is a real and patient-relevant signal. It is also drawn from small trials of varying design, and the lung-function measure did not reach significance. Both facts belong together.
Other clinical work
A phase I study of intravenous autologous MSCs in severe emphysema [4]and a pilot study of allogeneic umbilical-cord MSCs in COPD [3]have examined feasibility and safety. ⚠️ Both are small early-phase studies designed to detect harm, not to demonstrate benefit.
⚠️ Broader appraisals of cell therapy across lung disease have been explicitly titled around "progress and cautions" [11]— the field's own framing, and the right one.
The animal evidence, labelled
In elastase-induced emphysema models in mice, MSC administration reduced alveolar destruction and inflammatory infiltration and improved lung compliance. ⚠️ These are animal studies. They are the reason the clinical trials were run; they are not evidence about people, and the human trials that followed them were largely negative on function.
Safety — Read This Before Anything Else
This matters more here than on any other page we publish, because the population is frail, often hypoxaemic, frequently has cardiac comorbidity, and the treatment is an intravenous infusion.
What the data show. Weiss 2013 remains the best evidence: no infusional toxicities, no treatment-attributable deaths or serious adverse events, across 62 patients over two years [12]. A systematic review and meta-analysis of MSC trials across indications found no association with acute infusional toxicity, organ complications, infection, death or malignancy, with transient fever the one identified signal [17].
What is specific to the intravenous route. ⚠️ Infused cells do not distribute evenly. A large proportion are retained on first passage through the pulmonary capillary bed — the pulmonary first-pass effect, described in the literature as a major obstacle to intravenous cell delivery [16].
⚠️ This has been used as a selling point for lung disease — "the cells go to the lungs first, so it's ideal" — and that reasoning does not hold. Retention in the pulmonary microvasculature is a distribution fact, not an efficacy finding. It may contribute to a lung-directed effect; it also raises route-specific concerns, including interactions between infused cells and blood that are particular to intravascular delivery [15]. It cuts both ways, and a page selling an IV infusion for lung disease has an obligation to say so.
Reported effects are typically mild and short-lived: transient fever, fatigue, headache, infusion-site reactions.
What is not established: long-term outcomes beyond the trial windows; repeat-dosing safety; and any effect on survival, exacerbation frequency or oxygen requirement.
Not appropriate for: active infection · active malignancy · unstable cardiac disease · anyone whose treating physician has not been consulted.
Who This Might Suit — and Who It Does Not
Might reasonably consider it, after discussion with their respiratory physician: people with moderate COPD, stable disease, no active infection, realistic expectations, who understand this is investigational and are continuing all standard care.
Should not:
- Anyone with end-stage disease requiring continuous high-flow oxygen
- Anyone hoping to reduce or come off oxygen ⚠️ — there is no evidence for this, and the hope itself is the risk
- Anyone considering this instead of smoking cessation, pulmonary rehabilitation, inhaled therapy or transplant assessment
- Anyone with active infection or unstable comorbidity
Frequently Asked Questions
Will this cure my COPD?
No. COPD causes irreversible structural changes to lung tissue that cannot be undone by any current technology, including stem cells. MSC therapy is being investigated for its effect on inflammation, not on rebuilding lung.
Will it reduce my oxygen?
⛔ No trial has shown any reduction in oxygen requirement, and nothing here should lead you to change your oxygen. That decision belongs to the physician who prescribed it, on measured oxygenation.
Can I stop my inhalers or other medication?
No. Nothing on this page justifies changing any prescribed treatment. Continue everything unless your own physician changes it.
Is intravenous administration effective for lung conditions?
⚠️ That is not established. Infused cells are substantially retained on first pass through the lungs — a real phenomenon, described in the literature as an obstacle to intravenous delivery rather than an advantage [16]. It means the lungs receive a high proportion of the cells. It does not mean the treatment works, and the trial that tested it in COPD was negative on lung function and quality of life [12].
What did the trials actually show?
Negative on lung function, quality of life and exacerbations [12]; a significant 52-metre gain in walking distance in pooled analysis [13]; a fall in CRP in patients who started with elevated CRP [12]; and a reassuring two-year safety record [12]. That is the whole of it.
Are there side effects?
Generally mild — see the safety section. The route-specific considerations matter more than the reported side effects.
The Bottom Line
COPD is irreversible, and the interventions that change its course are stopping smoking and — for symptoms and function — pulmonary rehabilitation. Long-term oxygen therapy prolongs life in chronic hypoxaemia, and that is why it is prescribed.
Cell therapy in COPD has been tested properly and the honest summary is narrow: safe over two years in 62 patients, negative on lung function and quality of life, with a real 52-metre walking-distance signal in pooled small trials and a fall in an inflammatory marker.
If that is worth pursuing to you, pursue it alongside everything else — never instead of it, and never as a route away from your oxygen.